MXPA05008713A - Agente terapeutico para dano de medula espinal que comprende antagonista de interluceina-6. - Google Patents
Agente terapeutico para dano de medula espinal que comprende antagonista de interluceina-6.Info
- Publication number
- MXPA05008713A MXPA05008713A MXPA05008713A MXPA05008713A MXPA05008713A MX PA05008713 A MXPA05008713 A MX PA05008713A MX PA05008713 A MXPA05008713 A MX PA05008713A MX PA05008713 A MXPA05008713 A MX PA05008713A MX PA05008713 A MXPA05008713 A MX PA05008713A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- receptor
- spinal cord
- cells
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003046214 | 2003-02-24 | ||
PCT/JP2004/002111 WO2004073741A1 (ja) | 2003-02-24 | 2004-02-24 | インターロイキン-6アンタゴニストを含有する脊髄損傷治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05008713A true MXPA05008713A (es) | 2005-09-20 |
Family
ID=32905544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05008713A MXPA05008713A (es) | 2003-02-24 | 2004-02-24 | Agente terapeutico para dano de medula espinal que comprende antagonista de interluceina-6. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20060165696A1 (pt) |
EP (1) | EP1607100A4 (pt) |
JP (1) | JP4555924B2 (pt) |
KR (1) | KR101142624B1 (pt) |
CN (2) | CN100340294C (pt) |
AU (1) | AU2004212843B2 (pt) |
BR (1) | BRPI0407747A (pt) |
CA (1) | CA2516945A1 (pt) |
HK (1) | HK1088230A1 (pt) |
HR (1) | HRP20050837A2 (pt) |
IL (3) | IL170399A (pt) |
MX (1) | MXPA05008713A (pt) |
NO (1) | NO20054072L (pt) |
NZ (1) | NZ541928A (pt) |
PL (1) | PL378199A1 (pt) |
RU (2) | RU2358761C2 (pt) |
WO (1) | WO2004073741A1 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2312184T3 (es) | 1997-03-21 | 2009-02-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas. |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US8398980B2 (en) * | 2004-03-24 | 2013-03-19 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleuken-6 receptor |
WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
AR057941A1 (es) * | 2005-11-25 | 2007-12-26 | Univ Keio | Agentes terapeuticos para el cancer de prostata |
EP3135298B1 (en) | 2006-01-27 | 2018-06-06 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
CN101495146B (zh) | 2006-04-07 | 2012-10-17 | 国立大学法人大阪大学 | 肌肉再生促进剂 |
US20080015465A1 (en) * | 2006-06-15 | 2008-01-17 | Scuderi Gaetano J | Methods for diagnosing and treating pain in the spinal cord |
MX2009001110A (es) | 2006-08-03 | 2009-05-11 | Vaccinex Inc | Anticuerpos monoclonales anti-il-6 y usos de los mismos. |
TWI438208B (zh) | 2007-01-23 | 2014-05-21 | Chugai Pharmaceutical Co Ltd | 抑制慢性排斥反應之藥劑 |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
PL2164514T3 (pl) | 2007-05-21 | 2017-08-31 | Alderbio Holdings Llc | Przeciwciała przeciwko IL-6 i ich zastosowanie |
MX343879B (es) * | 2007-05-21 | 2016-11-25 | Alderbio Holdings Llc | Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados. |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US7709215B2 (en) * | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
ES2564635T3 (es) | 2008-05-13 | 2016-03-28 | Novimmune Sa | Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos |
KR101665729B1 (ko) * | 2008-06-05 | 2016-10-12 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신경침윤 억제제 |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
DK2493922T3 (en) | 2009-10-26 | 2017-04-24 | Hoffmann La Roche | Process for preparing a glycosylated immunoglobulin |
KR20120118088A (ko) | 2009-11-24 | 2012-10-25 | 앨더바이오 홀딩스 엘엘씨 | Ⅰl-6에 대한 항체 및 이들의 용도 |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
DK2578231T3 (da) | 2010-05-28 | 2022-12-12 | Chugai Pharmaceutical Co Ltd | Antitumor-t-celle-reaktionsforstærker |
CN103476793A (zh) | 2010-11-08 | 2013-12-25 | 基因技术公司 | 皮下施用的抗-il-6受体抗体 |
AU2011332817A1 (en) | 2010-11-23 | 2013-06-13 | Alder Biopharmaceuticals, Inc. | Anti-IL-6 antibodies for the treatment of anemia |
WO2012118813A2 (en) * | 2011-03-03 | 2012-09-07 | Apexigen, Inc. | Anti-il-6 receptor antibodies and methods of use |
BR112015032960B1 (pt) | 2013-07-04 | 2021-01-05 | F. Hoffmann-La Roche Ag | imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro |
US11484591B2 (en) | 2016-02-22 | 2022-11-01 | Ohio State Innovation Foundation | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
US11033496B2 (en) | 2017-03-17 | 2021-06-15 | The Regents Of The University Of Michigan | Nanoparticles for delivery of chemopreventive agents |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
KR20220064039A (ko) | 2020-11-11 | 2022-05-18 | 정성삼 | 척수 손상 예방 또는 치료용 조성물 |
KR102320780B1 (ko) | 2021-01-29 | 2021-11-02 | 정성삼 | 척추 통증 완화 및 척추 유연성 개선을 위한 조성물 및 이의 제조방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US521628A (en) | 1894-06-19 | Housekeeping-cabinet | ||
JP2898040B2 (ja) | 1990-01-26 | 1999-05-31 | 忠三 岸本 | gp130蛋白質に対する抗体 |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
AU7967294A (en) | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
IT1274350B (it) | 1994-12-06 | 1997-07-17 | Angeletti P Ist Richerche Bio | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 |
IT1274782B (it) | 1994-12-14 | 1997-07-24 | Angeletti P Ist Richerche Bio | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
ES2264135T3 (es) * | 1995-02-13 | 2006-12-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6. |
FR2733250B1 (fr) | 1995-04-21 | 1997-07-04 | Diaclone | Anticorps monoclonaux anti-gp130, et leurs utilisations |
US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
EP1027059A2 (en) * | 1997-10-27 | 2000-08-16 | Curis, Inc. | Enhancement of morphogen activity |
EP1053309B1 (en) * | 1998-02-13 | 2006-11-22 | The Wistar Institute | Compositions and methods for wound healing |
US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
-
2004
- 2004-02-24 CN CNB2004800050170A patent/CN100340294C/zh not_active Expired - Fee Related
- 2004-02-24 CA CA002516945A patent/CA2516945A1/en not_active Abandoned
- 2004-02-24 AU AU2004212843A patent/AU2004212843B2/en not_active Ceased
- 2004-02-24 US US10/546,149 patent/US20060165696A1/en not_active Abandoned
- 2004-02-24 JP JP2006519063A patent/JP4555924B2/ja not_active Expired - Fee Related
- 2004-02-24 KR KR1020057015579A patent/KR101142624B1/ko not_active IP Right Cessation
- 2004-02-24 RU RU2005130011/15A patent/RU2358761C2/ru not_active IP Right Cessation
- 2004-02-24 NZ NZ541928A patent/NZ541928A/xx not_active IP Right Cessation
- 2004-02-24 MX MXPA05008713A patent/MXPA05008713A/es active IP Right Grant
- 2004-02-24 EP EP04714014A patent/EP1607100A4/en not_active Withdrawn
- 2004-02-24 BR BRPI0407747-4A patent/BRPI0407747A/pt not_active IP Right Cessation
- 2004-02-24 WO PCT/JP2004/002111 patent/WO2004073741A1/ja active Application Filing
- 2004-02-24 CN CNA2007101481808A patent/CN101130077A/zh active Pending
- 2004-02-24 PL PL378199A patent/PL378199A1/pl unknown
-
2005
- 2005-08-21 IL IL170399A patent/IL170399A/en not_active IP Right Cessation
- 2005-09-01 NO NO20054072A patent/NO20054072L/no not_active Application Discontinuation
- 2005-09-22 HR HR20050837A patent/HRP20050837A2/xx not_active Application Discontinuation
-
2006
- 2006-08-02 HK HK06108578A patent/HK1088230A1/xx not_active IP Right Cessation
-
2009
- 2009-01-28 RU RU2009102845/15A patent/RU2009102845A/ru not_active Application Discontinuation
- 2009-07-28 IL IL200098A patent/IL200098A/en not_active IP Right Cessation
-
2010
- 2010-05-09 IL IL205618A patent/IL205618A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL170399A (en) | 2011-02-28 |
WO2004073741A8 (ja) | 2005-04-07 |
IL200098A (en) | 2012-10-31 |
IL205618A (en) | 2012-02-29 |
NO20054072L (no) | 2005-10-25 |
KR101142624B1 (ko) | 2012-06-15 |
HK1088230A1 (en) | 2006-11-03 |
HRP20050837A2 (en) | 2005-12-31 |
RU2005130011A (ru) | 2006-02-10 |
NZ541928A (en) | 2009-06-26 |
CA2516945A1 (en) | 2004-09-02 |
KR20060006004A (ko) | 2006-01-18 |
AU2004212843A1 (en) | 2004-09-02 |
EP1607100A1 (en) | 2005-12-21 |
JPWO2004073741A1 (ja) | 2007-08-23 |
AU2004212843B2 (en) | 2009-06-25 |
RU2358761C2 (ru) | 2009-06-20 |
JP4555924B2 (ja) | 2010-10-06 |
CN101130077A (zh) | 2008-02-27 |
RU2009102845A (ru) | 2010-08-10 |
NO20054072D0 (no) | 2005-09-01 |
BRPI0407747A (pt) | 2006-02-14 |
PL378199A1 (pl) | 2006-03-06 |
WO2004073741A1 (ja) | 2004-09-02 |
CN1753694A (zh) | 2006-03-29 |
CN100340294C (zh) | 2007-10-03 |
EP1607100A4 (en) | 2007-06-13 |
US20060165696A1 (en) | 2006-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004212843B2 (en) | Remedy for spinal injury containing interleukin-6 antagonist | |
US7320792B2 (en) | Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist | |
AU757261B2 (en) | Preventives or remedies for pancreatitis containing IL-6 antagonists as the active ingredient | |
US7498031B2 (en) | Therapeutic agents for inner ear disorders containing an IL-6 antagonist as an active ingredient | |
RU2195960C2 (ru) | Профилактический или терапевтический агент для лечения воспалительных заболеваний кишечника, содержащий в качестве активного ингредиента антагонист il-6 | |
CA2549467C (en) | A preventive agent for vasculitis | |
US9017677B2 (en) | Methods of treating a disease mediated by sensitized T cells | |
US8617550B2 (en) | Treatment of vasculitis with IL-6 antagonist | |
ZA200506706B (en) | Remedy for spinal injury containing interleukin-6 antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |